Cannabis & Wellness

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

With a high-yield dividend and perfect rent collection, NewLake Capital signals stability. But is this cannabis REIT a safe haven or just a high-risk reward?

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

Wellness brands often struggle to turn concepts into viable products. A Utah-based CDMO's new PhD-led center is bridging the gap from science to scale.

Herbs, Etc. just won Superfood of the Year. We explore how a legacy brand uses 57 years of integrity to innovate and thrive in today's crowded market.

Bee You Organics' recent award is more than a win for a small brand. It's a signal that the CPG landscape is being reshaped by waterless innovation.

With Thomas Winstanley at the helm, Edibles.com eyes dominance in the wellness-THC space. Can his CPG playbook conquer a booming but volatile market?

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

With foreign ownership now over 51%, a look at how South Korea's KT&G is attracting giants like BlackRock through performance, policy, and a surprising ESG edge.

Cymbiotika just named co-founder Durana Elmi its creative and experiential chief. It’s more than a title—it’s a blueprint for the future of wellness.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

In a landmark collaboration, ink giant INX is deploying an AI operating system to accelerate innovation, potentially cutting R&D time from months to days.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

A geo-targeting firm captured data from 1M cannabis consumers' phones to create a compliant ad audience. It's a strategic masterstroke, but it opens a new front in the battle over data privacy.

A major U.S. fund's increased stake in KT&G signals deep trust in its global expansion, backed by record Q1 growth and a promise of richer dividends.